Drug Profile
Adafosbuvir - Alios BioPharma
Alternative Names: AL335; ALS-335; JNJ-335; JNJ-64146212Latest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator Alios BioPharma
- Developer Alios BioPharma; Janssen
- Class Antivirals; Pyrimidine nucleotides; Uracil nucleotides
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis C
Most Recent Events
- 30 Nov 2022 No development reported - Phase-II for Hepatitis C (Combination therapy) in Moldova (PO)
- 30 Nov 2022 No development reported - Phase-II for Hepatitis C (Combination therapy) in United Kingdom (PO)
- 28 Jan 2020 Achillion Pharmaceuticals has been acquired by Alexion Pharmaceuticals